Cell and Gene Therapy Manufacturing Services Market | 2031
Cell and Gene Therapy Manufacturing Services Market | 2031
Segments - Cell and Gene Therapy Manufacturing Services Market by Type (Gene Therapy and Cell Therapy), Indication (Cancer, Cardiovascular Conditions, Ophthalmology, Orthopedics, and Others), Mode (Contract and In-house), End-user (Biotechnology Companies, Pharmaceutical, Research & Academic Institutes, and Others) and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5833
| 4.6 Rating
| 54 Reviews
| 189 Pages
| Format :
Report Description
Cell and Gene Therapy Manufacturing Services Market Outlook 2031
The global cell and gene therapy manufacturing services market size was USD 5 Bn in 2022 and is likely to reach USD 20.5 Bn by 2031, expanding at a CAGR of 17% during 2023–2031. The market growth is attributed to the rising public and private investments in the gene and cell therapy industry.
Increasing partnerships, acquisitions, and collaborations among contract development and manufacturing organization (CDMO) companies and pharmaceutical companies are projected to fuel the market during the assessment period. This helps in easy research and development and provides a smooth transition from formulating to finishing the medicinal substances. Additionally, the mutual profit between CDMO and pharmaceutical companies facilitates product innovation, which, in turn, propels the market. For instance,
-
On February 17, 2021, Charles River Laboratories announced the acquisition of Cognate BioServices, Inc., which is a key CDMO. The acquisition aims to accelerate the therapy programs of biopharma companies.
The market report states that the COVID-19 pandemic slightly affected the global cell and gene therapy manufacturing services market, as lockdowns were implemented across different countries, which disrupted manufacturing processes. This factor further affected the logistics and supply chain processes in the market. A significant rise in the number of product launches and certifications among the key market players was registered. This helped in market revenue generation during post-pandemic.
Cell and Gene Therapy Manufacturing Services Market Dynamics
Major Drivers
Surging number of chronic diseases such as cancer is driving the market. High prevalence of such conditions that require target-based therapies gives rise to the demand for cell and gene therapies, as they require specifically targeted treatments. Many companies are being granted research & development certifications. Furthermore, the rising number of collaborations, acquisitions, and partnerships is expected to boost the market.
Existing Restraints
High costs related to the operations of gene and cell therapy manufacturing are expected to affect the market growth. Additionally, the high complexity of manufacturing therapy products and their logistics affects the supply chain in the market, which restrains the market growth.
Emerging Opportunities
Rising number of innovative product launches by major players in the cell and gene therapy market is anticipated to create lucrative growth opportunities in the market. Moreover, increasing product applications among people with both acute and chronic conditions increases the demand for therapy services. Additionally, many companies are focusing on investing in the manufacture and development of their existing products to enhance the therapy performance. This is further expected to create growth opportunities in the market.
Scope of Cell and Gene Therapy Manufacturing Services Market Report
The report includes an assessment of trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Cell and Gene Therapy Manufacturing Services Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Type (Gene Therapy and Cell Therapy), Indication (Cancer, Cardiovascular Conditions, Ophthalmology, Orthopedics, and Others), Mode (Contract and In-house), and End-user (Biotechnology Companies, Pharmaceutical, Research & Academic Institutes, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Catalent, Inc; Charles River Laboratories; FUJIFILM Holdings Corporation; Lonza; Merck KGaA; Nikon Corporation; Oxford Biomedica PL; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and WuXi AppTec |
Cell and Gene Therapy Manufacturing Services Market Segment Insights
Type Segment Analysis
Based on type, the global market is segregated into gene therapy and cell therapy. The cell therapy segment is projected to expand at a considerable CAGR during the forecast period, due to the increasing number of cell therapies and treatments for cancer, infectious diseases, and urinary problems. Additionally, several key players are focusing on implementing growth strategies to develop their cell therapy capabilities, which, in turn, is propelling the segment.
The gene therapy segment accounts for a significant market share, due to the high dependency of cancer treatments on gene therapies. This therapy is known to be one of the most effective ways to discover and treat cancer cells, which is expected to fuel the segment during the forecast period.
Indication Segment Analysis
On the basis of indication, the cell and gene therapy manufacturing services market is divided into cancer, cardiovascular conditions, ophthalmology, orthopedics, and others. The cancer segment is expected to expand at a major growth rate during the projection period, due to the surging implementation of genetic engineering in oncology.
Evolving cancer disease cases across the world require advanced genetic solutions, which boosts the requirement for cell and gene therapy manufacturing services in oncology treatments. This factor drives the segment. Moreover, a rising number of product launches and approvals is anticipated to propel the segment. For instance,
-
On December 16, 2022, Ferring B.V. received approval from the US FDA for Adstiladrin. It is a vector-based gene therapy and is the first approved gene therapy for bladder cancer.
Mode Segment Analysis
Based on mode, the cell and gene therapy manufacturing services market is bifurcated into contract and in-house. The contract segment is expected to register robust growth during the assessment period. Many new firms have limited access to manufacturing capacity; thus, they require service providers, which boosts the segment. Several gene and cell therapy manufacturers outsource vector and gene therapy products, as it increases their productivity. These factors aid in the segment expansion.
End-user Segment Analysis
On the basis of end-user, the cell and gene therapy manufacturing services market is segmented into biotechnology companies, pharmaceutical, research & academic institutes, and others. The biotechnology companies segment is expected to register robust growth during the projection period, as they are actively involved in the utilization of therapy manufacturing service for research and development purposes.
These companies mainly focus on consumer safety and perspective, which helps them offer consumer-friendly gene and cell therapy manufacturing services. Furthermore, biotechnology companies have access to advanced technologies, hence, they use the technology in gene and cell therapy services, which further propels the segment.
The pharmaceutical segment is expected to hold a significant share of the market, due to the rising number of collaborations among contract development and manufacturing organizations and pharmaceutical companies. Moreover, biopharmaceutical companies are focused on investing in novel manufacturing techniques, expansion, and collaborations to cater to the increasing demand for therapies. This further propels the segment.
Regional Outlook
In terms of region, the global cell and gene therapy manufacturing services market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to the rising incidence of different cancer types among people in countries, including Canada and the US. Additionally, the presence of advanced infrastructure for effective research and development activities is further projected to drive the regional market. For instance,
-
On November 7, 2022, Charles River Laboratories announced the expansion of its cell therapy manufacturing and contract development facility. The expansion helps in commercial and clinical cell therapy manufacturing operations.
The market in Europe is anticipated to expand at a rapid pace during the forecast period, due to the rising incidence of chronic diseases. This is attributed to lifestyle habits, such as tobacco smoking, alcohol consumption, and unhealthy diets. Rising number of cancer patients in countries such as the UK is boosting the mortality rates. This factor boosts the requirement of cell and gene therapy. This further facilitates the growth of the market in the region.
Segments
The cell and gene therapy manufacturing services market has been segmented on the basis of
Type
- Gene Therapy
- Cell Therapy
Indication
- Cancer
- Cardiovascular Conditions
- Ophthalmology
- Orthopedics
- Others
Mode
- Contract
- In-house
End-user
- Biotechnology Companies
- Pharmaceutical
- Research & Academic Institutes
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Catalent, Inc
- Charles River Laboratories
- FUJIFILM Holdings Corporation
- Lonza
- Merck KGaA
- Nikon Corporation
- Oxford Biomedica PL
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Competitive Landscape
Key players operating in the global cell and gene therapy manufacturing services market include Catalent, Inc; Charles River Laboratories; FUJIFILM Holdings Corporation; Lonza; Merck KGaA; Nikon Corporation; Oxford Biomedica PL; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and WuXi AppTec.
Several companies are implementing market expansion & growth strategies such as divestitures, partnerships, acquisitions, R&D investments, mergers, collaboration, and product launches to boost their market share. For instance,
-
On January 15, 2021, Thermo Fisher Scientific Inc. acquired Henogen SA to evolve in the field of gene therapy and maintain consistent presence in the market.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Cell and Gene Therapy Manufacturing Services Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cell and Gene Therapy Manufacturing Services Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cell and Gene Therapy Manufacturing Services Market - Supply Chain
4.5. Global Cell and Gene Therapy Manufacturing Services Market Forecast
4.5.1. Cell and Gene Therapy Manufacturing Services Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cell and Gene Therapy Manufacturing Services Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cell and Gene Therapy Manufacturing Services Market Absolute $ Opportunity
5. Global Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
5.3.1. Gene Therapy
5.3.2. Cell Therapy
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
6.3.1. Biotechnology Companies
6.3.2. Pharmaceutical
6.3.3. Research & Academic Institutes
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
8. North America Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
8.4.1. Gene Therapy
8.4.2. Cell Therapy
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
8.7.1. Biotechnology Companies
8.7.2. Pharmaceutical
8.7.3. Research & Academic Institutes
8.7.4. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
9. Latin America Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
9.4.1. Gene Therapy
9.4.2. Cell Therapy
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
9.7.1. Biotechnology Companies
9.7.2. Pharmaceutical
9.7.3. Research & Academic Institutes
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
10. Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
10.4.1. Gene Therapy
10.4.2. Cell Therapy
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
10.7.1. Biotechnology Companies
10.7.2. Pharmaceutical
10.7.3. Research & Academic Institutes
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
11.4.1. Gene Therapy
11.4.2. Cell Therapy
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
11.7.1. Biotechnology Companies
11.7.2. Pharmaceutical
11.7.3. Research & Academic Institutes
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
12. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by Types
12.4.1. Gene Therapy
12.4.2. Cell Therapy
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size and Volume Forecast by End Users
12.7.1. Biotechnology Companies
12.7.2. Pharmaceutical
12.7.3. Research & Academic Institutes
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Cell and Gene Therapy Manufacturing Services Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Cell and Gene Therapy Manufacturing Services Market: Market Share Analysis
13.2. Cell and Gene Therapy Manufacturing Services Distributors and Customers
13.3. Cell and Gene Therapy Manufacturing Services Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Catalent, Inc
13.4.2. Charles River Laboratories
13.4.3. FUJIFILM Holdings Corporation
13.4.4. Lonza
13.4.5. Merck KGaA
13.4.6. Nikon Corporation
13.4.7. Oxford Biomedica PL
13.4.8. Takara Bio Inc.
13.4.9. Thermo Fisher Scientific Inc.
13.4.10. WuXi AppTec
Methodology
Related Reports
Some other reports from this category!
Our Clients
